Toth Financial Advisory Corp Purchases 18,478 Shares of Bristol-Myers Squibb (NYSE:BMY)

Toth Financial Advisory Corp lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 25.3% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 91,496 shares of the biopharmaceutical company’s stock after acquiring an additional 18,478 shares during the period. Toth Financial Advisory Corp’s holdings in Bristol-Myers Squibb were worth $5,580,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BMY. Truist Financial Corp boosted its stake in Bristol-Myers Squibb by 3.9% during the 4th quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company’s stock valued at $90,335,000 after purchasing an additional 60,365 shares during the last quarter. Quilter Plc boosted its position in shares of Bristol-Myers Squibb by 56.6% during the fourth quarter. Quilter Plc now owns 107,818 shares of the biopharmaceutical company’s stock valued at $6,098,000 after buying an additional 38,977 shares during the last quarter. Advyzon Investment Management LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter worth about $458,000. Covenant Asset Management LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter worth about $279,000. Finally, Polar Asset Management Partners Inc. purchased a new position in Bristol-Myers Squibb in the 4th quarter worth about $16,651,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

BMY opened at $48.42 on Monday. The company has a 50 day simple moving average of $49.34 and a two-hundred day simple moving average of $55.02. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The firm has a market cap of $98.54 billion, a P/E ratio of -10.95, a PEG ratio of 2.07 and a beta of 0.38. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analysts’ expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($4.40) EPS. Equities analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the business’s stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BMY shares. Wall Street Zen downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday. UBS Group dropped their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a report on Friday, April 11th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. The Goldman Sachs Group reissued a “neutral” rating and set a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Finally, Argus upgraded Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.